Cargando…

Alpha-Galactosylceramide/CD1d-Antibody Fusion Proteins Redirect Invariant Natural Killer T Cell Immunity to Solid Tumors and Promote Prolonged Therapeutic Responses

Major progress in cancer immunotherapies have been obtained by the use of tumor targeting strategies, in particular with the development of bi-functional fusion proteins such as ImmTacs or BiTes, which engage effector T cells for targeted elimination of tumor cells. Given the significance of invaria...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Lianjun, Donda, Alena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2017
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5672503/ https://www.ncbi.nlm.nih.gov/pubmed/29163493 http://dx.doi.org/10.3389/fimmu.2017.01417

Ejemplares similares

Identification of distinct human invariant natural killer T-cell response phenotypes to alpha-galactosylceramide
por: Croudace, Joanne E, et al.
Publicado: (2008)

CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: α-Galactosylceramide and Beyond
por: King, Lisa A., et al.
Publicado: (2018)

Expansion of invariant natural killer T cells from systemic lupus erythematosus patients by alpha-Galactosylceramide and IL-15
por: Hsu, Chien-Ya, et al.
Publicado: (2021)

Corrigendum: CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: α-Galactosylceramide and Beyond
por: King, Lisa A., et al.
Publicado: (2018)

Exogenous Activation of Invariant Natural Killer T Cells by α-Galactosylceramide Reduces Pneumococcal Outgrowth and Dissemination Postinfluenza
por: Barthelemy, Adeline, et al.
Publicado: (2016)

Activation of Invariant Natural Killer T Cells Redirects the Inflammatory Response in Neonatal Sepsis
por: Bolognese, Alexandra C., et al.
Publicado: (2018)

α-galactosylceramide-stimulated invariant natural killer T-cells play a protective role in murine vulvovaginal candidiasis by Candida albicans
por: Abe, Masahiro, et al.
Publicado: (2021)

Natural Killer Dendritic Cells Enhance Immune Responses Elicited by α-Galactosylceramide-Stimulated Natural Killer T Cells
por: Lee, Sung Won, et al.
Publicado: (2013)

Activation of Invariant Natural Killer T Cells by α-Galactosylceramide Attenuates the Development of Angiotensin II-Mediated Abdominal Aortic Aneurysm in Obese ob/ob Mice
por: Saito, Akimichi, et al.
Publicado: (2021)

CD1d-mediated Recognition of an α-Galactosylceramide by Natural Killer T Cells Is Highly Conserved through Mammalian Evolution
por: Brossay, Laurent, et al.
Publicado: (1998)

Natural Killer T Cell Ligand α-Galactosylceramide Enhances Protective Immunity Induced by Malaria Vaccines
por: Gonzalez-Aseguinolaza, Gloria, et al.
Publicado: (2002)

α‐galactosylceramide generates lung regulatory T cells through the activated natural killer T cells in mice
por: Chen, Qianhui, et al.
Publicado: (2018)

CD1d-antibody fusion proteins target iNKT cells to the tumor and trigger long-term therapeutic responses
por: Corgnac, Stéphanie, et al.
Publicado: (2012)

Natural Killer T Cell Ligand α‐Galactosylceramide Inhibited Lymph Node Metastasis of Highly Metastatic Melanoma Cells
por: Nakui, Minoru, et al.
Publicado: (1999)

Prolonged Activation of Invariant Natural Killer T Cells and T(H)2-Skewed Immunity in Stroke Patients
por: Wong, Connie H. Y., et al.
Publicado: (2017)

Repeated administration of alpha-galactosylceramide ameliorates experimental lupus nephritis in mice
por: Uchida, Takahiro, et al.
Publicado: (2018)

Invariant Natural Killer T and Mucosal-Associated Invariant T Cells in Asthmatic Patients
por: Lezmi, Guillaume, et al.
Publicado: (2018)

Antitumor Responses of Invariant Natural Killer T Cells
por: Altman, Jennie B., et al.
Publicado: (2015)

Immunometabolic Activation of Invariant Natural Killer T Cells
por: Ververs, Francesca A., et al.
Publicado: (2018)

Antigen specificity of invariant natural killer T-cells
por: Birkholz, Alysia M., et al.
Publicado: (2015)

The two faces of invariant natural killer T cells
por: Walton, Emma L.
Publicado: (2015)

Metabolism in Invariant Natural Killer T Cells: An Overview
por: Yarosz, Emily L., et al.
Publicado: (2021)

Invariant natural killer T cells in lung diseases
por: Jeong, Dongjin, et al.
Publicado: (2023)

Superior Protection against Malaria and Melanoma Metastases by a C-glycoside Analogue of the Natural Killer T Cell Ligand α-Galactosylceramide
por: Schmieg, John, et al.
Publicado: (2003)

Alpha-galactosylceramide enhances mucosal immunity to oral whole-cell cholera vaccines
por: Davitt, Christopher J. H., et al.
Publicado: (2019)

Lineage Differentiation Program of Invariant Natural Killer T Cells
por: Kwon, Dong-il, et al.
Publicado: (2017)

Therapeutic Potential of Invariant Natural Killer T Cells in Autoimmunity
por: Van Kaer, Luc, et al.
Publicado: (2018)

CD1d-restricted Help To B Cells By Human Invariant Natural Killer T Lymphocytes
por: Galli, Grazia, et al.
Publicado: (2003)

Prophylactic Sublingual Immunization with Mycobacterium tuberculosis Subunit Vaccine Incorporating the Natural Killer T Cell Agonist Alpha-Galactosylceramide Enhances Protective Immunity to Limit Pulmonary and Extra-Pulmonary Bacterial Burden in Mice
por: Khan, Arshad, et al.
Publicado: (2017)

Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity
por: Zhang, Congcong, et al.
Publicado: (2021)

α‐Galactosylceramide‐activated murine NK1.1(+) invariant‐NKT cells in the myometrium induce miscarriages in mice
por: Ichikawa, Tomoko, et al.
Publicado: (2016)

Antibody‐dependent cellular cytotoxicity toward neuroblastoma enhanced by activated invariant natural killer T cells
por: Mise, Naoko, et al.
Publicado: (2016)

Natural Killer T-Cell Agonist α-Galactosylceramide and PD-1 Blockade Synergize to Reduce Tumor Development in a Preclinical Model of Colon Cancer
por: Wang, Ying, et al.
Publicado: (2020)

Defective NKT Cell Activation by CD1d+ TRAMP Prostate Tumor Cells Is Corrected by Interleukin-12 with alpha-Galactosylceramide
por: Nowak, Michael, et al.
Publicado: (2010)

iNKT/CD1d-antitumor immunotherapy significantly increases the efficacy of therapeutic CpG/peptide-based cancer vaccine
por: Corgnac, Stéphanie, et al.
Publicado: (2014)

Activation of Natural Killer T Cells by α-Galactosylceramide Rapidly Induces the Full Maturation of Dendritic Cells In Vivo and Thereby Acts as an Adjuvant for Combined CD4 and CD8 T Cell Immunity to a Coadministered Protein
por: Fujii, Shin-ichiro, et al.
Publicado: (2003)

Harnessing the Power of Invariant Natural Killer T Cells in Cancer Immunotherapy
por: Bedard, Melissa, et al.
Publicado: (2017)

Glucosylceramide Synthase Is Involved in Development of Invariant Natural Killer T Cells
por: Popovic, Zoran V., et al.
Publicado: (2017)

Harnessing invariant natural killer T cells to control pathological inflammation
por: Bharadwaj, Nikhila S., et al.
Publicado: (2022)

Insights Into Mucosal-Associated Invariant T Cell Biology From Studies of Invariant Natural Killer T Cells
por: Garner, Lucy C., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_rk0h0qdgnoovrbi96f9lc05qts